Mymetics Corp (MYMX)

[Work Harder]

HIV clades also vary in prevalence throughout the world. For example, HIV clade B is found mostly throughout North America and Europe, while the epidemic in South Africa and India is due to HIV clade C. Researchers are therefore trying to develop an AIDS vaccine candidate that offers the broadest possible protection.

Clade classification refers to the different protein sequences that distinguish the circulating viruses and not the way the human immune system recognizes or reacts to HIV, so the importance of such matching is still in question. Scientists are also still trying to determine the type and magnitude of immune response required for protection, so clinical trials to determine the immunogenicity of vaccine candidates in relevant populations remain critical.

Merck and the HIV Vaccine Trials Network (HVTN) are now completing site preparations in South Africa for a second Phase IIb "test of concept" trial with the company's clade B-based adenovirus serotype 5 (Ad5) vaccine candidate, known as MRKAd5. The candidate is currently being evaluated in another Phase IIb trial in North America, South America, the Caribbean, and Australia. The addition of a South African trial marks the first time this candidate will be evaluated in a population where the circulating clade of HIV, clade C, does not match that in the vaccine.

http://www.vaxreport.org/index.php?option=com_content&view=article&id=726&Itemid=884

That was older so this should be figured out by now

https://www.avert.org/professionals/hiv-science/types-strains

The dominant HIV subtype in the Americas, Western Europe and Australasia is subtype B. As a result, the great majority of HIV clinical research has been conducted in populations where subtype B predominates, despite this subtype representing only 12% of global HIV infections.

& Ruth is work on HIV-1

On the other hand, antiretroviral drugs (ARVs), although largely developed in relation to subtype B, have generally proven to be effective against a wide range of subtypes.9 10 However, infection with subtype C virus has been associated with poorer ART treatment outcomes in Sweden.11 12 13